September 6, 2012 - LifeVest Showcased at Heart Failure Society of America 2012

MEDIA CONTACT:  

Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
degan@zoll.com  

ZOLL LIFEVEST WEARABLE DEFIBRILLATOR TO BE SHOWCASED AT HEART FAILURE SOCIETY OF AMERICA 2012 ANNUAL MEETING

September 6, 2012—CHELMSFORD, MASS.—ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it will display the LifeVest® Wearable Defibrillator in Booth #312 at the Heart Failure Society of America (HFSA) Annual Meeting being held from September 9-12 in Seattle.

An estimated 5.7 million Americans are currently living with heart failure, and it is estimated that by 2030, an additional 3 million people will be impacted. Patients with heart failure are at high risk of sudden cardiac arrest (SCA), especially immediately following an acute event such as hospitalization for heart failure decompensation or myocardial infarction.

The LifeVest is worn by patients at risk for SCA, providing protection during their changing condition and while permanent SCA risk has not been established. The LifeVest allows a patient’s physician time to assess his or her long-term arrhythmic risk and make appropriate plans.

“The LifeVest is an important therapy in the continuum of care for patients with heart failure, protecting patients during this time of highest risk while they are being optimized on medical therapy,” said Marshal Linder, President of ZOLL LifeVest. “Continuing to educate the cardiology community about SCA risks associated with heart failure is an important step in protecting more patients and saving more lives.”

The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

The LifeVest is used for a wide range of patient conditions or situations, including following a heart attack, before or after bypass surgery or stent placement, as well as for those with cardiomyopathy or congestive heart failure that places them at particular risk.

The LifeVest is covered by most health plans in the United States, including commercial, state, and federal plans.

For more information, go to www.zoll.com or call 1-800-543-3267.

About ZOLL Medical Corporation


ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care. For more information, visit www.zoll.com.

The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 25,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.

Copyright © 2012 ZOLL Medical Corporation. All rights reserved. LifeVest and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. All product names are the property of their respective owners.